A Study to Evaluate the Safety, Tolerability, PK, and PD Effects of AZD2389 in Participants With Liver Fibrosis and Compensated Cirrhosis.

Clinical trial NCT06750276 · COMPLETED

Trial details

NCT number: NCT06750276
Sponsor: AstraZeneca
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Liver Fibrosis Hepatic Cirrhosis

Start date: 2024-12-06
Primary completion: 2025-07-28
Enrollment: 40

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.